(Total Views: 577)
Posted On: 08/19/2020 10:05:04 AM
Post# of 149199
I noticed the FDA put the approval of Plasma therapy for Covid on hold today due to "weak data from the study". The other two headlines below show the complete failure in Covid trials by IL-6 drugs. These drugs are from some very heavy hitters like Roche, Sanofi and Regeneron. Meanwhile, Leronlimab has achieved what Dr Fauci has requested since the onset of Covid. That is to provide statistically significant data in a 2:1, double blinded FDA trial. In addition, Leronlimab has outstanding EIND data and a safety profile that is second to none. You really have wonder why this molecule gets no traction.
F.D.A.’s Emergency Approval of Blood Plasma Is Now on Hold
Government health leaders including Dr. Francis S. Collins and Dr. Anthony S. Fauci urged caution last week, citing weak data from the country’s largest plasma study.
Roche declares a Ph3 failure for Covid-19 as the IL-6 repurposing theory bites the dust
John Carroll
Editor & Founder
Another big IL-6 drug has failed to move the needle for Covid-19 patients, leaving that particular field of repurposed drug R&D on the ropes for the pandemic.
IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trial
Hopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results from the first large-scale trial of Sanofi and Regeneron’s Kevzara.July 3, 2020
F.D.A.’s Emergency Approval of Blood Plasma Is Now on Hold
Government health leaders including Dr. Francis S. Collins and Dr. Anthony S. Fauci urged caution last week, citing weak data from the country’s largest plasma study.
Roche declares a Ph3 failure for Covid-19 as the IL-6 repurposing theory bites the dust
John Carroll
Editor & Founder
Another big IL-6 drug has failed to move the needle for Covid-19 patients, leaving that particular field of repurposed drug R&D on the ropes for the pandemic.
IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trial
Hopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results from the first large-scale trial of Sanofi and Regeneron’s Kevzara.July 3, 2020
(3)
(0)Scroll down for more posts ▼
